Everolimus (INN) (earlier code name RAD001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.

postmenopausal women with a type of breast cancer known as advanced hormone receptor-positive HER2-negative breast cancer along with Aromasin (exemestane) after treatment with other medication has not worked.

adults with a type of pancreatic cancer known as pancreatic neuroendocrine tumor (PNET) that has progressed and can not be treated with surgery.

adults with a type of advanced kidney cancer known as renal cell carcinoma (RCC) when treatment with other medications has not worked.

people with the following types of tumors that are seen with a genetic condition called tuberous sclerosis complex (TSC):

adults with a type of kidney tumor called renal angiomyolipoma when the tumor does not need surgery right away.

adults and children with a type of brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot be removed with surgery.

For advanced breast cancer neuroendocrine tumors (NET) advanced kidney cancer and renal angiomyolipoma with TSC the recommended dose of everolimus tablets is 10 mg to be taken once daily at the same time every day. Take either consistently with food or consistently without food. Everolimus tablets should be swallowed whole with a glass of water. Do not break or crush tablets.

Kidney transplantation: starting dose of 0.75 mg twice daily as soon as possible after transplantation.

Liver transplantation: starting dose of 1.0 mg twice daily starting 30 days after transplantation.

Take consistently with or without food at the same time as cyclosporine or tacrolimus.

Afinitor Disperz (everolimus):

The recommended dose when used to treat brain tumor called subependymal giant cell astrocytoma (SEGA) is 4.5 mg/m2 once daily.

When treating TSC-Associated Partial-Onset Seizures the recommended dose is 5 mg/m2 orally once daily.